NanoLogix, Inc. NNLX

NNLX Company Overview

NanoLogix, Inc. (OTC Pink: NNLX) is a U.S.-based biotechnology and diagnostic development company focused on rapid microbial detection, infectious disease diagnostics, and laboratory testing technologies. The company has historically concentrated on proprietary culture and detection systems intended to accelerate the identification of bacterial and fungal pathogens compared with conventional laboratory methods. NanoLogix has operated within the broader healthcare, biotechnology, and in vitro diagnostics industries, with a particular emphasis on clinical microbiology applications.

The company’s principal business activities have centered on the development and commercialization potential of rapid diagnostic platforms, including technologies associated with tuberculosis testing and automated microbial growth detection. Public disclosures and market filings indicate that NanoLogix has pursued collaborations and licensing opportunities tied to healthcare diagnostics and laboratory services, although publicly available financial and operational disclosures have at times been limited relative to larger publicly traded biotechnology firms. Data regarding current large-scale commercial adoption and revenue concentration is inconclusive based on available public sources.